HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen.

AbstractBACKGROUND:
The cytoprotective agent, ecabet sodium, inhibits urease activity and growth of Helicobacter pylori.
AIM:
To evaluate the efficacy and safety of ecabet sodium-based eradication of H. pylori infection, compared with a lansoprazole-based regimen, in a randomized multicentre study.
SUBJECTS AND METHODS:
A total of 120 H. pylori-positive patients were assigned to one of two treatment regimens for 2 weeks: ecabet sodium 1 g b.d., amoxicillin 500 mg t.d.s. and clarithromycin 400 mg b.d. (EAC: 60 patients); or lansoprazole 30 mg (o.m.) with the same antimicrobial agents (LAC: 60 patients). Cure of infection was assessed by a 13C-urea breath test 1 month after completion of treatment.
RESULTS:
One patient in the EAC group and two in the LAC group did not complete therapy because of an adverse event, and three did not undergo the 13C-urea breath test. Cure rates for the intention-to-treat, all-patients-treated and per protocol analysis in the EAC group were 85%, 86% and 88%, respectively, whereas those in the LAC group were 85%, 88% and 91%. There were no significant differences in cure rate or adverse events between the two regimens.
CONCLUSIONS:
Ecabet sodium in combination with amoxicillin and clarithromycin is as effective as lansoprazole-based eradication therapy for H. pylori.
AuthorsK Adachi, S Ishihara, T Hashimoto, K Hirakawa, N Ishimura, M Niigaki, T Kaji, A Kawamura, H Sato, H Fujishiro, S Hattori, M Watanabe, Y Kinoshita
JournalAlimentary pharmacology & therapeutics (Aliment Pharmacol Ther) Vol. 15 Issue 8 Pg. 1187-91 (Aug 2001) ISSN: 0269-2813 [Print] England
PMID11472321 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Bacterial Agents
  • Carbon Isotopes
  • Diterpenes
  • Diterpenes, Abietane
  • Penicillins
  • Lansoprazole
  • ecabet
  • Amoxicillin
  • Urea
  • Pepsin A
  • Urease
  • Clarithromycin
  • Omeprazole
Topics
  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Adult
  • Aged
  • Amoxicillin (therapeutic use)
  • Anti-Bacterial Agents (therapeutic use)
  • Breath Tests
  • Carbon Isotopes
  • Clarithromycin (therapeutic use)
  • Diterpenes (therapeutic use)
  • Diterpenes, Abietane
  • Drug Therapy, Combination (therapeutic use)
  • Female
  • Helicobacter Infections (drug therapy)
  • Helicobacter pylori (drug effects)
  • Humans
  • Lansoprazole
  • Male
  • Middle Aged
  • Omeprazole (analogs & derivatives, therapeutic use)
  • Penicillins (therapeutic use)
  • Pepsin A (antagonists & inhibitors)
  • Prospective Studies
  • Treatment Outcome
  • Urea (analysis, blood)
  • Urease (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: